Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care
Population-wide screening of children for presymptomatic early-stage type 1 diabetes is gaining momentum. Studies have demonstrated feasibility and acceptance, and shown that the rate of progression to clinical stage 3 diabetes is similar if islet autoantibody-positive early-stage type 1 diabetes is identified from general population or first-degree relative screening.1,2 Moreover, in conjunction with an education and follow-up package, screening significantly reduces the rates of ketoacidosis, symptoms, and hospitalisation.